As of today (2026-06-29), the Forward Annual Dividend Yield of Applied BioCode is 0.00%.
As of today (2026-06-29), the Trailing Annual Dividend Yield of Applied BioCode is 0.00%.
TPE:6598's Forward Dividend Yield % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.15 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Applied BioCode Forward Dividend Yield % Related Terms
TPE:6598 vs ABT, SYK, MDT: Forward Dividend Yield % Comparison
For the Medical Devices subindustry, Applied BioCode's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied BioCode Forward Dividend Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Applied BioCode's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Applied BioCode (TPE:6598) has a Forward Dividend Yield % of 0.00% as of Jun. 29, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Applied BioCode and its competitors. According to the industry distribution chart, Applied BioCode ranks #999999 out of 315 companies in the Medical Devices & Instruments industry.
Is Applied BioCode's Forward Dividend Yield % too high?
Applied BioCode's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Applied BioCode ranks #999999 out of 315 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Applied BioCode has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's Forward Dividend Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Applied BioCode ranks #999999 out of 315 companies for Forward Dividend Yield %. This places Applied BioCode in the lower half of its industry. The industry median Forward Dividend Yield % is 2.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Devices & Instruments company?
The median Forward Dividend Yield % among Medical Devices & Instruments companies is 2.15, based on 315 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Applied BioCode and its competitors. For the Medical Devices & Instruments industry, the median Forward Dividend Yield % is 2.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Applied BioCode's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Fairly Valued. The stock's GF Value™ is NT$23.33, compared to a current price of NT$22.80 — trading 2.3% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Applied BioCode's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current Forward Dividend Yield % is 0.00% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Applied BioCode (TPE:6598) Overvalued in 2026?
Based on GuruFocus' analysis, Applied BioCode stock appears to be undervalued.
The current stock price of NT$22.80 is trading 2.3% below its estimated GF Value™ of NT$23.33.
GuruFocus considers Applied BioCode to be Fairly Valued.
Key valuation signals for TPE:6598:
Forward Dividend Yield %: 0.00%
GF Value™: NT$23.33 vs. price of NT$22.80 (2.3% below fair value)
No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
74GF Score
Get the complete analysis for TPE:6598
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6598 has been successfully added to your 